Lv31
366 积分 2024-05-15 加入
An open-label randomized active-controlled phase II clinical study to assess the efficacy and safety of afuresertib plus paclitaxel versus paclitaxel in patients with platinum-resistant ovarian cancer (PROFECTA-II/GOG-3044)
5小时前
已完结
Engasertib in Hereditary Hemorrhagic Telangiectasia
21天前
已完结
The efficacy and safety of PI3K and AKT inhibitors for patients with cancer: A systematic review and network meta-analysis
1个月前
已完结
Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial
1个月前
已完结
Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer
1个月前
已完结
Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer
2个月前
已完结
The PI3K/AKT signaling pathway in cancer: Molecular mechanisms and possible therapeutic interventions
2个月前
已完结
Claudin 18.2 as a novel therapeutic target
2个月前
已完结
Lysine Acetyltransferases (KATs) in Disguise: Diseases Implications
3个月前
已完结
Strategies for targeting cytokines in inflammatory bowel disease
3个月前
已完结
皖公网安备34019202002308
